Compare MIST & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 140.4M |
| IPO Year | 2019 | 2020 |
| Metric | MIST | CNTB |
|---|---|---|
| Price | $0.37 | $0.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $3.86 | ★ $5.71 |
| AVG Volume (30 Days) | ★ 2.0M | 569.3K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $215.89 | $7,473.67 |
| Revenue Next Year | $157.01 | $240.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.55 |
| 52 Week High | $3.06 | $3.82 |
| Indicator | MIST | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 34.22 |
| Support Level | N/A | N/A |
| Resistance Level | $0.84 | $2.62 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 2.26 | 16.72 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.